Patent litigation Europe summit 2026

Patent litigation Europe summit 2026

We’re proud to be a Platinum Partner at the Patent Litigation Europe Summit 2026, taking place in Amsterdam from 19 to 21 January.

This leading event brings together IP specialists, industry leaders and legal practitioners to address the key issues shaping patent litigation across Europe and beyond.

On 21 January, our experts take part in two morning discussions:

  • 09:10 – 10:10 AM | Pharma & Biotech Track
    Richard Roberts joins an expert panel for “Preliminary Injunction Review for the Life Science Sector”, examining the latest developments and practical strategies for securing or challenging injunctions across the UPC, Europe and the United States.
  • 09:10 – 10:10 AM | Tech & Innovation Track
    Peter Finnie presents “Understanding Different Perspectives Surrounding Patent Quality and Its Impact Upon the Patent Ecosphere”, sharing insights on how differing views of patent quality influence enforcement strategies, licensing leverage and portfolio management, and what this means for technology-driven industries.

We look forward to meeting peers and contributing to discussions that shape the future of IP litigation.

Supporting Nottingham Pride through pro bono trade mark expertise

Supporting Nottingham Pride through pro bono trade mark expertise

Winning at the EPO: Proven specialists in EPO oppositions

Winning at the EPO: Proven specialists in EPO oppositions

Protecting antibody innovations beyond composition claims

Protecting antibody innovations beyond composition claims

HPV vaccine success and the IP opportunities ahead

HPV vaccine success and the IP opportunities ahead

Fake weight-loss medications and new enforcement possibilities

Fake weight-loss medications and new enforcement possibilities

CJEU rules on hosting defence for EU platforms

CJEU rules on hosting defence for EU platforms

Potter Clarkson ranked in Managing IP's IP STARS 2026

Potter Clarkson ranked in Managing IP's IP STARS 2026

Combination therapies: IP considerations for synergistic biologic products

Combination therapies: IP considerations for synergistic biologic products

See All News